Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2012

Open Access 01-12-2012 | Research article

Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer

Authors: Robert S Phillips, Ros Wade, Thomas Lehrnbecher, Lesley A Stewart, Alex J Sutton

Published in: BMC Medicine | Issue 1/2012

Login to get access

Abstract

Background

Febrile neutropenia is a frequently occurring and occasionally life-threatening complication of treatment for childhood cancer. Many biomarkers have been proposed as predictors of adverse events. We aimed to undertake a systematic review and meta-analysis to summarize evidence on the discriminatory ability of initial serum biomarkers of febrile neutropenic episodes in children and young people.

Methods

This review was conducted in accordance with the Center for Reviews and Dissemination Methods, using three random effects models to undertake meta-analysis. It was registered with the HTA Registry of systematic reviews, CRD32009100485.

Results

We found that 25 studies exploring 14 different biomarkers were assessed in 3,585 episodes of febrile neutropenia. C-reactive protein (CRP), pro-calcitonin (PCT), and interleukin-6 (IL6) were subject to quantitative meta-analysis, and revealed huge inconsistencies and heterogeneity in the studies included in this review. Only CRP has been evaluated in assessing its value over the predictive value of simple clinical decision rules.

Conclusions

The limited data available describing the predictive value of biomarkers in the setting of pediatric febrile neutropenia mean firm conclusions cannot yet be reached, although the use of IL6, IL8 and procalcitonin warrant further study.
Appendix
Available only for authorised users
Literature
1.
Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JWW: Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer. 2006, 42: 2183-2190. 10.1016/j.ejca.2006.06.006.CrossRefPubMed
2.
Freycon F, Trombert-Paviot B: Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the childhood cancer registry of the Rhone-Alpes region in France (ARCERRA). Pediatr Blood Cancer. 2008, 50: 1213-1220. 10.1002/pbc.21506.CrossRefPubMed
3.
Hargrave DR, Hann IM: Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, × and XI). Br J Haematol. 2001, 112: 293-299. 10.1046/j.1365-2141.2001.02543.x.CrossRefPubMed
4.
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T: Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004, 22: 4384-4393. 10.1200/JCO.2004.01.191.CrossRefPubMed
5.
Ammann RA, Simon A, de Bont ES: Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?. Pediatr Blood Cancer. 2005, 45: 244-247. 10.1002/pbc.20287.CrossRefPubMed
6.
Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC: Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child. 2007, 92: 495-498. 10.1136/adc.2006.102699.CrossRefPubMedPubMedCentral
7.
Boragina M, Patel H: Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer. 2007, 48: 521-526. 10.1002/pbc.20810.CrossRefPubMed
8.
Phillips B, Wade R, Stewart LA, Sutton AJ: Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer. 2010, 46: 2950-2964. 10.1016/j.ejca.2010.05.024.CrossRefPubMedPubMedCentral
9.
Santolaya M, Cofre J, Beresi V: C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis. 1994, 18: 589-595. 10.1093/clinids/18.4.589.CrossRefPubMed
10.
Nijhuis CO, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM: Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol. 2005, 23: 7437-7444. 10.1200/JCO.2004.00.5264.CrossRef
11.
Lehrnbecher T, Fleischhack G, Hanisch M, Deinlein F, Simon A, Bernig T, Chanock SJ, Klingebiel T: Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Hematologica. 2004, 89: 234-236.
12.
Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, Wu A, Lawlor C, Dalton H: Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med. 2005, 6: 129-135. 10.1097/01.PCC.0000149317.15274.48.CrossRefPubMed
13.
Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K: The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection. 2008, 36: 396-407. 10.1007/s15010-008-7374-y.CrossRefPubMed
14.
Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T: Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol. 26: 453-456.
15.
Dubos F, Martinot A, Gendrel D, Breart G, Chalumeau M: Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol. 2009, 22: 288-293. 10.1097/WCO.0b013e32832b240e.CrossRefPubMed
16.
Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M: A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997, 99: 580-588. 10.1046/j.1365-2141.1997.4453255.x.CrossRefPubMed
17.
Centre for Reviews and Dissemination: Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care. 2009, York, UK: University of York
18.
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM: Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999, 282: 1061-1066. 10.1001/jama.282.11.1061.CrossRefPubMed
19.
Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J: The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003, 3: 25-10.1186/1471-2288-3-25.CrossRefPubMedPubMedCentral
20.
Centre for Reviews and Dissemination: Systematic reviews of clinical tests. Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care. 2009, Centre for Reviews and Dissemination. York, UK: University of York, 109-156.
21.
Stata Statistical Software: Release 10. Stata Statistical Software: Release 10. 2007, College Station, TX:StataCorp LP
22.
Harbord R: METANDI: Stata module to perform meta-analysis of diagnostic accuracy. METANDI: Stata Module to Perform Meta-analysis of Diagnostic Accuracy. 2008, Bristol, UK: Department of Social Medicine, University of Bristol
23.
Dwamena BA: MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. MIDAS: Stata Module for Meta-analytical Integration of Diagnostic Test Accuracy Studies. 2009, Chestnut Hill, MA: Boston College Department of Economics
24.
Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical literature: III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994, 271: 703-707. 10.1001/jama.1994.03510330081039.CrossRefPubMed
25.
Lunn D, Thomas A, Best N, Spiegelhalter D: WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000, 10: 325-337. 10.1023/A:1008929526011.CrossRef
26.
Ammann RA, Hirt A, Luthy AR, Aebi C: Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003, 41: 436-443. 10.1002/mpo.10320.CrossRefPubMed
27.
El-Maghraby SM, Moneer MM, Ismail MM, Shalaby LM, El-Mahallawy HA: The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007, 29: 131-136. 10.1097/MPH.0b013e3180308770.CrossRefPubMed
28.
Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D: Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007, 30: E75-85.PubMed
29.
Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki C, Athanassiadou F, Frydas S, Kotsis A, Catriu D: Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med. 2005, 5: 60-65. 10.1007/s10238-005-0067-2.CrossRefPubMed
30.
Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR: Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis J. 1992, 11: 708-712. 10.1097/00006454-199209000-00007.CrossRefPubMed
31.
Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M: Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis. 2006, 25: 413-415. 10.1007/s10096-006-0143-x.CrossRefPubMed
32.
Riikonen P, Jalanko H, Hovi L, Saarinen UM: Fever and neutropenia in children with cancer: diagnostic parameters at presentation. Acta Paediatr. 1993, 82: 271-275. 10.1111/j.1651-2227.1993.tb12658.x.CrossRefPubMed
33.
Secmeer G, Devrim I, Kara A, Ceyhan M, Cengiz B, Kutluk T, Buyukpamukcu M, Yetgin S, Tuncer M, Uludag AK, Tezer H, Yildirim I: Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol. 2007, 29: 107-111. 10.1097/MPH.0b013e3180320b5b.CrossRefPubMed
34.
Santolaya ME, Alvarez AM, Becker A, Cofre J, Enriquez N, O'Ryan M, Paya E, Pilorget J, Salgado C, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M: Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001, 19: 3415-3421.PubMed
35.
Spasova MI, Terzieva DD, Tzvetkova TZ, Stoyanova AA, Mumdzhiev IN, Yanev IB, Genev ED: Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. Folia Med (Plovdiv). 2005, 47: 46-52.
36.
Riikonen P, Saarinen UM, Teppo AM, Metsarinne K, Fyhrquist F, Jalanko H: Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis. 1992, 166: 432-436. 10.1093/infdis/166.2.432.CrossRefPubMed
37.
Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kuhl J: Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999, 29: 414-419. 10.1086/520224.CrossRefPubMed
38.
Diepold M, Noellke P, Duffner U, Kontny U, Berner R: Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis. 2008, 8: 28-10.1186/1471-2334-8-28.CrossRefPubMedPubMedCentral
39.
Lehrnbecher T, Fleischhack G, Hanisch M, Deinlein F, Simon A, Bernig T, Chanock SJ, Klingebiel T: Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Haematologica. 2004, 89: 234-236.PubMed
40.
Riley RD, Sauerbrei W, Altman DG: Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009, 100: 1219-1229. 10.1038/sj.bjc.6604999.CrossRefPubMedPubMedCentral
41.
Frakking FN, van de Wetering MD, Brouwer N, Dolman KM, Geissler J, Lemkes B, Caron HN, Kuijpers TW: The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer. 2006, 42: 909-916. 10.1016/j.ejca.2005.10.027.CrossRefPubMed
42.
Schlapbach LJ, Aebi C, Hansen AG, Hirt A, Jensenius JC, Ammann RA: H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin Exp Immunol. 2009, 157: 83-89. 10.1111/j.1365-2249.2009.03957.x.CrossRefPubMedPubMedCentral
43.
Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001, 54: 774-781. 10.1016/S0895-4356(01)00341-9.CrossRefPubMed
44.
Hozo S, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005, 5: 13-10.1186/1471-2288-5-13.CrossRefPubMedPubMedCentral
45.
Kyzas PA, Denaxa-Kyza D, Ioannidis JPA: Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007, 99: 236-243. 10.1093/jnci/djk032.CrossRefPubMed
46.
Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J: Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004, 140: 189-202.CrossRefPubMed
47.
Knudsen TB, Kristiansen TB: Issues pertaining to data extraction and classification and publication bias in meta analysis of the diagnostic accuracy of markers for bacterial infection. Clin Infect Dis. 2005, 40: 1372-1373. 10.1086/429507.CrossRefPubMed
48.
Sanders S, Barnett A, Correa-Velez I, Coulthard M, Doust J: Systematic review of the diagnostic accuracy of c-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. J Pediatr. 2008, 153: 570-574. 10.1016/j.jpeds.2008.04.023.CrossRefPubMed
49.
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004, 39: 206-217. 10.1086/421997.CrossRefPubMed
50.
Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, Tidefelt U: Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004, 36: 365-371. 10.1080/00365540410020217.CrossRefPubMed
51.
52.
de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA: Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol. 1999, 107: 375-380. 10.1046/j.1365-2141.1999.01707.x.CrossRefPubMed
53.
Oude Nijhuis C, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, Ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM: Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol. 2005, 23: 7437-7444. 10.1200/JCO.2004.00.5264.CrossRefPubMed
54.
Metadata
Title
Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer
Authors
Robert S Phillips
Ros Wade
Thomas Lehrnbecher
Lesley A Stewart
Alex J Sutton
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-10-6

Other articles of this Issue 1/2012

BMC Medicine 1/2012 Go to the issue

Research article

Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Correspondence

Is belief larger than fact: expectations, optimism and reality for translational stem cell research

Commentary

A commentary on evidenced-based parenting programs: redressing misconceptions of the empirical support for Triple P

Debate

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Research article

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

Research article

Rest versus exercise as treatment for patients with low back pain and Modic changes. a randomized controlled clinical trial